Table 1.
Patient demographic, hemodynamic, and metabolic characteristics at inclusion
| All ( n = 35) | Lactate improvers ( n = 17) | Lactate nonimprovers ( n = 18) | P value | |
|---|---|---|---|---|
| Age (years) | 65 ± 13 | 63 ± 14 | 69 ± 11 | 0.2 |
| Male | 22 (63) | 10 (59) | 12 (67) | 0.8 |
| Etiology | ||||
| Respiratory | 8 (23) | 4 (24) | 4 (22) | |
| Abdominal | 14 (40) | 7 (41) | 7 (39) | 0.8 |
| Urinary tract | 4 (11) | 3 (18) | 1 (6) | |
| Soft tissue | 5 (14) | 1 (6) | 4 (22) | |
| Other | 4 (11) | 2 (12) | 2 (11) | |
| SAPS II | 49 ± 11 | 47 ± 9 | 50 ± 12 | 0.5 |
| SOFA score (day 1) | 9 ± 3 | 9 ± 3 | 9 ± 3 | 0.6 |
| Mechanical ventilation | 28 (80) | 14 (82) | 14 (78) | 0.5 |
| Heart rate (beats per minute) | 103 ± 14 | 103 ± 17 | 104 ± 13 | 0.8 |
| MAP (mmHg) | 78 ± 12 | 82 ± 11 | 71 ± 10 | 0.08 |
| Norepinephrine use (%) | 100 | 100 | 100 | 1 |
| Norepinephrine dose (μg/kg/minute) | 0.86 ± 0.65 | 0.66 ± 0.5 | 1.01 ± 0.75 | 0.05 |
| Hemoglobin (g/dl) | 11.2 ± 2.0 | 12.2 ± 1.7 | 9.9 ± 2.0 | 0.02 |
| ScvO2 (%) | 71 ± 8 | 71 ± 8 | 72 ± 8 | 0.7 |
| Lactate (mg/dl) | 38 ± 48 | 30 ± 15 | 46 ± 65 | 0.8 |
| PcvaCO2 gap (mmHg) | 5.6 ± 2.1 | 5.1 ± 1.9 | 6.1 ± 2.3 | 0.09 |
| PcvaCO2/CavO2 ratio (mmHg · dl/ml O2) | 1.6 ± 0.7 | 1.3 ± 0.4 | 1.8 ± 0.8 | 0.02 |
| O2ER | 0.26 ± 0.09 | 0.25 ± 0.09 | 0.25 ± 0.08 | 0.9 |
| ICU length of stay (days) | 15 ± 10 | 17 ± 14 | 13 ± 10 | 0.5 |
| Mortality | 10 (29) | 3 (18) | 7 (39) | 0.2 |
Data presented as mean ± standard deviation or number (%). MAP, mean arterial pressure; O2ER, oxygen extraction ratio; PcvaCO2 gap, central venous-to-arterial carbon dioxide difference; PcvaCO2/CavO2 ratio, central venous-to-arterial carbon dioxide difference/arterial-to-central venous oxygen content difference ratio; SAPS, Simplified Acute Physiological Score; ScvO2, central venous oxygen saturation; SOFA, Sequential Organ Failure Assessment.